+关注
HongWang
暂无个人介绍
IP属地：未知
172
关注
89
粉丝
0
主题
0
勋章
主贴
热门
HongWang
2021-10-03
like
2 Ridiculously Cheap Growth Stocks to Buy
HongWang
2021-03-19
[微笑]
1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should
HongWang
2021-02-16
[得意]
With Biden going big, Wall Street economists are growing bullish on the US economy
HongWang
2021-02-03
[开心]
抱歉，原内容已删除
HongWang
2021-02-03
[微笑]
Neo Group to acquire 51% stake in snack maker
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3563929170003666,"uuid":"3563929170003666","gmtCreate":1603548344118,"gmtModify":1613485272596,"name":"HongWang","pinyin":"hongwang","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/98c4dd0e0d1f9e2e40e2885b36ade4a0","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":89,"headSize":172,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.12","exceedPercentage":"60.45%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.25","exceedPercentage":"80.92%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":867188655,"gmtCreate":1633226568725,"gmtModify":1633226570462,"author":{"id":"3563929170003666","authorId":"3563929170003666","name":"HongWang","avatar":"https://static.tigerbbs.com/98c4dd0e0d1f9e2e40e2885b36ade4a0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/867188655","repostId":"2172643049","repostType":4,"repost":{"id":"2172643049","pubTimestamp":1633222044,"share":"https://www.laohu8.com/m/news/2172643049?lang=&edition=full","pubTime":"2021-10-03 08:47","market":"us","language":"en","title":"2 Ridiculously Cheap Growth Stocks to Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2172643049","media":"Motley Fool","summary":"Though these companies have recorded solid financials of late, investors are overlooking them.","content":"<p>Growth stocks can sometimes trade at inflated valuations because of their attractive long-term potential. So if you get the opportunity to invest in a growth stock that isn't trading at a premium but rather at a discount, you should definitely consider adding it to your portfolio.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> unloved growth stocks that trade at low multiples of future earnings and look incredibly cheap right now are <b>Bristol Myers Squibb</b> (NYSE:BMY) and <b>ViacomCBS </b>(NASDAQ:VIAC).<img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>1. Bristol Myers Squibb</h2>\n<p>Healthcare giant Bristol Myers Squibb is a stock that investors could easily be overlooking right now. From afar, its financials look horrible. For the trailing 12 months, the company incurred a net loss of $5 billion. So investors relying on stock screeners to try and find good buys could easily overlook Bristol Myers -- and they have. Year to date, shares of the healthcare stock are down about 2% while the <b>S&P 500</b> has soared 16%.</p>\n<p>But investors who dig a little deeper will find a slightly different story. The huge loss is in fact due to a massive research and development charge of more than $11 billion that the company incurred for its acquisition of MyoKardia, a clinical-stage biopharmaceutical company that develops cardiovascular medicine. That negatively impacted the fourth quarter of last year and is still impacting the trailing 12-month numbers.</p>\n<p>In the past two quarters, however, the company has been firmly in the black. Through the first six months of 2021, Bristol Myers' revenue of $22.8 billion has risen 9% year over year, and its net earnings have flipped from a $846 million loss in 2020 to a $3.1 billion profit.</p>\n<p>Meanwhile, with free cash flow of $11.7 billion over the past four quarters, its dividend also looks rock-solid. The company has paid out $4.2 billion during that time while also making stock repurchases of $4.5 billion. This serves as further proof that accounting income alone can't be relied on to assess the health of a company's operations. Cash flow is arguably a much more important indicator than net income -- and by that metric, Bristol Myers is doing just fine.</p>\n<p>So a closer look at Bristol Myers suggests the company is a much safer buy than its numbers may appear at first glance. A forward price-to-earnings (P/E) ratio can be useful for companies when a bad quarter or two have weighed on their numbers. And by that measure, Bristol Myers only trades at a P/E of 8 — incredibly cheap compared to other healthcare stocks, such as <b>Merck</b> (NYSE:MRK) and <b>Amgen </b>(NASDAQ:AMGN), which both trade at about 13 times their future profits.</p>\n<p>Finally, there's the 3.3% dividend yield, which is more than twice as much as the S&P 500's 1.3%. Whether you're a growth investor or love a good dividend, this is an underrated healthcare stock that should be on your radar.</p>\n<h2>2. ViacomCBS</h2>\n<p>Another stock that's trading at a low valuation is ViacomCBS. At a forward P/E multiple of just 10, it's nowhere near the premium that investors are paying for other companies in the entertainment and streaming business, such as <b>Netflix</b> (NASDAQ:NFLX) and <b>Walt Disney </b>(NYSE:DIS) -- trading at 56 and 70 times their forward profits, respectively.</p>\n<p>Admittedly, ViacomCBS' Paramount+ streaming service isn't as popular, and that could be a reason investors aren't giving the stock as much of a chance. Overall, the company has a total of 42 million global streaming subscribers (including Paramount+ and other smaller services such as Pluto TV). By comparison, Netflix has more than 200 million subscribers while Disney+ now has 116 million.</p>\n<p>But Paramount+ doesn't have to be the top streaming service for ViacomCBS to be an attractive buy. In its latest quarter ended June 30, the company reported that streaming revenue grew 92% to $983 million from the year-ago period and advertising revenue rose 24% to $2.1 billion.</p>\n<p>The lone blemish for the company was its \"licensing and other\" segment, which fell 36% to $1.2 billion -- hurt by the absence of theatrical releases during the pandemic. That kept the company's sales growth relatively modest last quarter, rising 8% to $6.6 billion. However, as the economy continues to recover from the pandemic, those numbers should get stronger.</p>\n<p>Meanwhile, ViacomCBS also offers investors an above-average dividend yield of 2.4%. And with free cash of $2.6 billion over the past 12 months, it is generating more than enough to cover the $601 million in dividends it paid out during that time.</p>\n<p>So, while Paramount+ may be an afterthought for some investors looking to go into top streaming stocks, that in fact could be an opportunity. ViacomCBS shares still fly under the radar -- up just 8% this year. As subscribers continue to increase and revenues improve, it may just be a matter of time before the stock takes off.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Ridiculously Cheap Growth Stocks to Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Ridiculously Cheap Growth Stocks to Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-03 08:47 GMT+8 <a href=https://www.fool.com/investing/2021/10/02/2-ridiculously-cheap-growth-stocks-to-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks can sometimes trade at inflated valuations because of their attractive long-term potential. So if you get the opportunity to invest in a growth stock that isn't trading at a premium but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/02/2-ridiculously-cheap-growth-stocks-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QNETCN":"纳斯达克中美互联网老虎指数","NFLX":"奈飞"},"source_url":"https://www.fool.com/investing/2021/10/02/2-ridiculously-cheap-growth-stocks-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2172643049","content_text":"Growth stocks can sometimes trade at inflated valuations because of their attractive long-term potential. So if you get the opportunity to invest in a growth stock that isn't trading at a premium but rather at a discount, you should definitely consider adding it to your portfolio.\nTwo unloved growth stocks that trade at low multiples of future earnings and look incredibly cheap right now are Bristol Myers Squibb (NYSE:BMY) and ViacomCBS (NASDAQ:VIAC).\nImage source: Getty Images.\n1. Bristol Myers Squibb\nHealthcare giant Bristol Myers Squibb is a stock that investors could easily be overlooking right now. From afar, its financials look horrible. For the trailing 12 months, the company incurred a net loss of $5 billion. So investors relying on stock screeners to try and find good buys could easily overlook Bristol Myers -- and they have. Year to date, shares of the healthcare stock are down about 2% while the S&P 500 has soared 16%.\nBut investors who dig a little deeper will find a slightly different story. The huge loss is in fact due to a massive research and development charge of more than $11 billion that the company incurred for its acquisition of MyoKardia, a clinical-stage biopharmaceutical company that develops cardiovascular medicine. That negatively impacted the fourth quarter of last year and is still impacting the trailing 12-month numbers.\nIn the past two quarters, however, the company has been firmly in the black. Through the first six months of 2021, Bristol Myers' revenue of $22.8 billion has risen 9% year over year, and its net earnings have flipped from a $846 million loss in 2020 to a $3.1 billion profit.\nMeanwhile, with free cash flow of $11.7 billion over the past four quarters, its dividend also looks rock-solid. The company has paid out $4.2 billion during that time while also making stock repurchases of $4.5 billion. This serves as further proof that accounting income alone can't be relied on to assess the health of a company's operations. Cash flow is arguably a much more important indicator than net income -- and by that metric, Bristol Myers is doing just fine.\nSo a closer look at Bristol Myers suggests the company is a much safer buy than its numbers may appear at first glance. A forward price-to-earnings (P/E) ratio can be useful for companies when a bad quarter or two have weighed on their numbers. And by that measure, Bristol Myers only trades at a P/E of 8 — incredibly cheap compared to other healthcare stocks, such as Merck (NYSE:MRK) and Amgen (NASDAQ:AMGN), which both trade at about 13 times their future profits.\nFinally, there's the 3.3% dividend yield, which is more than twice as much as the S&P 500's 1.3%. Whether you're a growth investor or love a good dividend, this is an underrated healthcare stock that should be on your radar.\n2. ViacomCBS\nAnother stock that's trading at a low valuation is ViacomCBS. At a forward P/E multiple of just 10, it's nowhere near the premium that investors are paying for other companies in the entertainment and streaming business, such as Netflix (NASDAQ:NFLX) and Walt Disney (NYSE:DIS) -- trading at 56 and 70 times their forward profits, respectively.\nAdmittedly, ViacomCBS' Paramount+ streaming service isn't as popular, and that could be a reason investors aren't giving the stock as much of a chance. Overall, the company has a total of 42 million global streaming subscribers (including Paramount+ and other smaller services such as Pluto TV). By comparison, Netflix has more than 200 million subscribers while Disney+ now has 116 million.\nBut Paramount+ doesn't have to be the top streaming service for ViacomCBS to be an attractive buy. In its latest quarter ended June 30, the company reported that streaming revenue grew 92% to $983 million from the year-ago period and advertising revenue rose 24% to $2.1 billion.\nThe lone blemish for the company was its \"licensing and other\" segment, which fell 36% to $1.2 billion -- hurt by the absence of theatrical releases during the pandemic. That kept the company's sales growth relatively modest last quarter, rising 8% to $6.6 billion. However, as the economy continues to recover from the pandemic, those numbers should get stronger.\nMeanwhile, ViacomCBS also offers investors an above-average dividend yield of 2.4%. And with free cash of $2.6 billion over the past 12 months, it is generating more than enough to cover the $601 million in dividends it paid out during that time.\nSo, while Paramount+ may be an afterthought for some investors looking to go into top streaming stocks, that in fact could be an opportunity. ViacomCBS shares still fly under the radar -- up just 8% this year. As subscribers continue to increase and revenues improve, it may just be a matter of time before the stock takes off.","news_type":1},"isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":350183257,"gmtCreate":1616166209179,"gmtModify":1634526897949,"author":{"id":"3563929170003666","authorId":"3563929170003666","name":"HongWang","avatar":"https://static.tigerbbs.com/98c4dd0e0d1f9e2e40e2885b36ade4a0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[微笑] ","listText":"[微笑] ","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/350183257","repostId":"1190757715","repostType":4,"repost":{"id":"1190757715","pubTimestamp":1616161968,"share":"https://www.laohu8.com/m/news/1190757715?lang=&edition=full","pubTime":"2021-03-19 21:52","market":"us","language":"en","title":"1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should","url":"https://stock-news.laohu8.com/highlight/detail?id=1190757715","media":"Motley Fool","summary":"It might be a surprise to find out that two investors with virtually opposite approaches -- one who ","content":"<p>It might be a surprise to find out that two investors with virtually opposite approaches -- one who invests in large, cheap, iconic companies and the other who rose to fame on the heels of her outlandishly bullish (and accurate) predictions about \"overvalued\" stocks -- would have the same company in their portfolios. Perhaps the bigger surprise is the stock you might expect them to both own that they don't. Let's take a look at the two companies in question and what these successful investors must see.</p><p><b>The surprising stock they both own</b></p><p>First, it's doubtful that Warren Buffett actually bought<b>Snowflake</b>(NYSE:SNOW), the cloud data warehouse-as-a-service company. In recent years, lieutenants Todd Combs and Ted Weschler have been making more of the investment decisions, and the $750 million in stock<b>BerkshireHathaway</b>(NYSE:BRK.A)(NYSE:BRK.B)purchased before theinitial public offering (IPO)certainly doesn't match the investment style of the legendary nonagenarian. In fact, Buffett hasn't bought an IPO since<b>Ford</b> in 1956. The company does fit the style of Cathie Wood at ARK Invest, a global asset management company focused on disruptive innovation. That said, Snowflake is putting up numbers that would get any investor's attention.</p><p>The company recently reported its full fiscal year earnings, and the growth was jaw-dropping. Fourth-quarter revenue of $178 million was up 116% year over year. Topping that, remaining performance obligations, what customers have signed on to buy, was up 213% over the same point last year. The company has 77 customers that spend more than $1 million per year. That number is up from 65 just three months earlier. Management is projecting between 92% and 96% revenue growth for the current year. Snowflake posted an operating margin of negative 92%. Losing money never sounds good, but that is closer to profitability than the negative 135% for the year ending January 2020 or the negative 192% in 2019. If the company really wanted to turn a profit it could just curb its spending on sales and marketing.</p><p>It may not be a typical Buffett stock, but Snowflake definitely fits the mold of Wood's investments. The ARK founder has become synonymous with innovation, building a portfolio around futuristic themes such as genomics, space exploration, mobility-as-a-service, and the next-generation internet. It's the last theme, encompassing artificial intelligence and cloud computing, where Snowflake fits. The company's pay-as-you-consume, real-time access to data and analytical tools is a giant leap forward compared to the slow, bogged-down daily or weekly updates companies have long come to accept with managing their internal data warehouses.</p><p>Another stock in ARK's portfolio touches both the data-related and genomic revolution strategy. Based on his other holdings, it's actually surprising Buffett doesn't own it too.</p><p><b>The surprising stock they don't both own</b></p><p>The Oracle of Omaha has been buying up the stocks of pharmaceutical companies in the past year. In the third quarter of 2020 he added shares of<b>Pfizer</b>(NYSE:PFE),<b>AbbVie</b>(NYSE:ABBV),<b>Merck</b>(NYSE:MRK), and<b>BristolMyersSquibb</b>(NYSE:BMY). Every member of that group gives investors between 3% and 5% in dividends annually. Other than Bristol Myers, they all hover around a $200 billion market cap as well, and Bristol Myers is nearly as large at $136 billion. Similarly,<b>Novartis</b>(NYSE:NVS)is a $211 billion company yielding 3.8%. Perhaps the reason Buffett hasn't bought this big pharma stock is that it is a Swiss company. It turns out, Buffett favors American brands in food, cola, and apparently drugmakers.</p><p>Novartis did catch the eye of Wood, thanks to its work toward developing a leading digital and data science platform for drug discovery. Although it isn't a pure play on any of ARK's strategies, Wood considers it a deep value pick, to be held through a bull market and then sold in times of volatility to add to higher-conviction growth names that get beaten down.</p><p><b>Portfolio juxtaposition</b></p><p>It may be counterintuitive for an investor who prides himself on unemotional investing to buy into one of the hottest IPOs of last year, but once Snowflake started trading, the investment doubled almost immediately. Similarly, few would think someone famous for a $4,000 price target on<b>Tesla</b>and presentations that literally map out the future of entire industries would own a nearly 4% dividend paying pharmaceutical company with no growth. However, there is a great lesson in these examples.</p><p>Don't settle for the labels Wall Street places on companies or investors. Value and growth are just words. Investors may have tendencies that define them in the public eye, but that oversimplification may obscure the characteristics that draw their interest in an investment. Although Buffett likely didn't buy shares of Snowflake, it may have been the customer loyalty, leadership team, and consistent march toward profitability that made Combs or Weschler comfortable buying Snowflake shares. Wood may have a lot of fast-growing companies that don't make a profit, but it's the innovation that compels her to invest, not just growth rate. In the case of Novartis, innovation came in the form of a mega-cap pharmaceutical company.</p><p>Instead of focusing on the labels Wall Street slaps on a company or following Warren Buffett or Cathie Wood into the stock, try to identify the characteristics of the business that they find compelling. Try approaching the company as if you were going to inherit it, learning how dedicated customers are, where money gets spent to attract new ones, or what advantages it has over competitors. These answers will lead to a more informed investment decision and better outcomes over time.</p><p>It turns out, both Snowflake and Novartis are compelling to different types of investors for a variety of reasons. Exploring those reasons can teach us a lot more about investing than focusing solely on who owns them. The more we know about a company, the easier it is to figure out whether the nextsell-off is something to fear or a great opportunity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-19 21:52 GMT+8 <a href=https://www.fool.com/investing/2021/03/19/1-stock-warren-buffett-and-cathie-wood-have-in-com/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It might be a surprise to find out that two investors with virtually opposite approaches -- one who invests in large, cheap, iconic companies and the other who rose to fame on the heels of her ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/19/1-stock-warren-buffett-and-cathie-wood-have-in-com/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/19/1-stock-warren-buffett-and-cathie-wood-have-in-com/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190757715","content_text":"It might be a surprise to find out that two investors with virtually opposite approaches -- one who invests in large, cheap, iconic companies and the other who rose to fame on the heels of her outlandishly bullish (and accurate) predictions about \"overvalued\" stocks -- would have the same company in their portfolios. Perhaps the bigger surprise is the stock you might expect them to both own that they don't. Let's take a look at the two companies in question and what these successful investors must see.The surprising stock they both ownFirst, it's doubtful that Warren Buffett actually boughtSnowflake(NYSE:SNOW), the cloud data warehouse-as-a-service company. In recent years, lieutenants Todd Combs and Ted Weschler have been making more of the investment decisions, and the $750 million in stockBerkshireHathaway(NYSE:BRK.A)(NYSE:BRK.B)purchased before theinitial public offering (IPO)certainly doesn't match the investment style of the legendary nonagenarian. In fact, Buffett hasn't bought an IPO sinceFord in 1956. The company does fit the style of Cathie Wood at ARK Invest, a global asset management company focused on disruptive innovation. That said, Snowflake is putting up numbers that would get any investor's attention.The company recently reported its full fiscal year earnings, and the growth was jaw-dropping. Fourth-quarter revenue of $178 million was up 116% year over year. Topping that, remaining performance obligations, what customers have signed on to buy, was up 213% over the same point last year. The company has 77 customers that spend more than $1 million per year. That number is up from 65 just three months earlier. Management is projecting between 92% and 96% revenue growth for the current year. Snowflake posted an operating margin of negative 92%. Losing money never sounds good, but that is closer to profitability than the negative 135% for the year ending January 2020 or the negative 192% in 2019. If the company really wanted to turn a profit it could just curb its spending on sales and marketing.It may not be a typical Buffett stock, but Snowflake definitely fits the mold of Wood's investments. The ARK founder has become synonymous with innovation, building a portfolio around futuristic themes such as genomics, space exploration, mobility-as-a-service, and the next-generation internet. It's the last theme, encompassing artificial intelligence and cloud computing, where Snowflake fits. The company's pay-as-you-consume, real-time access to data and analytical tools is a giant leap forward compared to the slow, bogged-down daily or weekly updates companies have long come to accept with managing their internal data warehouses.Another stock in ARK's portfolio touches both the data-related and genomic revolution strategy. Based on his other holdings, it's actually surprising Buffett doesn't own it too.The surprising stock they don't both ownThe Oracle of Omaha has been buying up the stocks of pharmaceutical companies in the past year. In the third quarter of 2020 he added shares ofPfizer(NYSE:PFE),AbbVie(NYSE:ABBV),Merck(NYSE:MRK), andBristolMyersSquibb(NYSE:BMY). Every member of that group gives investors between 3% and 5% in dividends annually. Other than Bristol Myers, they all hover around a $200 billion market cap as well, and Bristol Myers is nearly as large at $136 billion. Similarly,Novartis(NYSE:NVS)is a $211 billion company yielding 3.8%. Perhaps the reason Buffett hasn't bought this big pharma stock is that it is a Swiss company. It turns out, Buffett favors American brands in food, cola, and apparently drugmakers.Novartis did catch the eye of Wood, thanks to its work toward developing a leading digital and data science platform for drug discovery. Although it isn't a pure play on any of ARK's strategies, Wood considers it a deep value pick, to be held through a bull market and then sold in times of volatility to add to higher-conviction growth names that get beaten down.Portfolio juxtapositionIt may be counterintuitive for an investor who prides himself on unemotional investing to buy into one of the hottest IPOs of last year, but once Snowflake started trading, the investment doubled almost immediately. Similarly, few would think someone famous for a $4,000 price target onTeslaand presentations that literally map out the future of entire industries would own a nearly 4% dividend paying pharmaceutical company with no growth. However, there is a great lesson in these examples.Don't settle for the labels Wall Street places on companies or investors. Value and growth are just words. Investors may have tendencies that define them in the public eye, but that oversimplification may obscure the characteristics that draw their interest in an investment. Although Buffett likely didn't buy shares of Snowflake, it may have been the customer loyalty, leadership team, and consistent march toward profitability that made Combs or Weschler comfortable buying Snowflake shares. Wood may have a lot of fast-growing companies that don't make a profit, but it's the innovation that compels her to invest, not just growth rate. In the case of Novartis, innovation came in the form of a mega-cap pharmaceutical company.Instead of focusing on the labels Wall Street slaps on a company or following Warren Buffett or Cathie Wood into the stock, try to identify the characteristics of the business that they find compelling. Try approaching the company as if you were going to inherit it, learning how dedicated customers are, where money gets spent to attract new ones, or what advantages it has over competitors. These answers will lead to a more informed investment decision and better outcomes over time.It turns out, both Snowflake and Novartis are compelling to different types of investors for a variety of reasons. Exploring those reasons can teach us a lot more about investing than focusing solely on who owns them. The more we know about a company, the easier it is to figure out whether the nextsell-off is something to fear or a great opportunity.","news_type":1},"isVote":1,"tweetType":1,"viewCount":320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":382408375,"gmtCreate":1613471848597,"gmtModify":1634553544937,"author":{"id":"3563929170003666","authorId":"3563929170003666","name":"HongWang","avatar":"https://static.tigerbbs.com/98c4dd0e0d1f9e2e40e2885b36ade4a0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[得意] ","listText":"[得意] ","text":"[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/382408375","repostId":"1108705396","repostType":4,"repost":{"id":"1108705396","pubTimestamp":1613469786,"share":"https://www.laohu8.com/m/news/1108705396?lang=&edition=full","pubTime":"2021-02-16 18:03","market":"us","language":"en","title":"With Biden going big, Wall Street economists are growing bullish on the US economy","url":"https://stock-news.laohu8.com/highlight/detail?id=1108705396","media":"CNN Business","summary":"New York (CNN Business) The Covid-ravaged American economy was on the verge of slipping into a doubl","content":"<p><b>New York (CNN Business) </b>The Covid-ravaged American economy was on the verge of slipping into a double-dip recession at the end of 2020. The pandemic was intensifying,gridlock paralyzed Washington and millions of families were about to lose crucial benefits.</p>\n<p>Fast forward two months, and the economy is still struggling-- but confidence in the recovery is growing, rapidly.</p>\n<p>Economists are swiftly upgrading their GDP and unemployment forecasts and pulling forward the date when the Federal Reserve will be able to lift rock-bottom interest rates. Goldman Sachs is predicting the US economy will grow at the fastest clip in more than three decades.</p>\n<p>The renewed optimism is being driven by two major factors: the health crisis is easing and Uncle Sam is coming to the rescue with staggering amounts of aid-- hundreds of billions more than seemed to be in the cards just months ago.</p>\n<p>After supplying $4 trillion of relief last year, Washington is expected to pump in another $2 trillion of deficit-financed support in 2021, according to Moody's Analytics. That represents more than a quarter of annual US GDP.</p>\n<p>\"That is a lot of economic juice,\" Mark Zandi, chief economist at Moody's Analytics, told CNN Business.</p>\n<p>The turning point happened last month when Democrats took narrow control of the US Senate by sweeping the runoff races in Georgia. That opened a path for President Joe Biden's $1.9 trillion American Rescue Plan, which features $1,400 stimulus checks, enhanced unemployment benefits and a $350 billion lifeline to state and local governments.</p>\n<p><b>'Summer mini-boom'</b></p>\n<p>Before the Georgia elections, Zandi didn't think the US economy would return to full employment (a strong labor market with 4% unemployment) until the spring or summer of 2023. Now, he expects that achievement to happen next spring, echoing a forecast by Treasury Secretary Janet Yellen.</p>\n<p>\"Super-charged fiscal policy\" means the argument for the US economy growing faster than its peers \"seems to get stronger day-by-day,\" economists at Bank of America wrote in a recent report to clients.</p>\n<p>Oxford Economics chief US economist Gregory Daco is calling for a \"summer mini-boom\" in the United States and 5.9% GDP growth in 2021.</p>\n<p>Likewise, Jefferies economists say \"explosive income growth (courtesy of fiscal stimulus) is likely to propel US GDP 6.4% higher this year and nearly 5% next year.\"</p>\n<p>\"If anything, our forecast might be too conservative,\" Jefferies told clients in a recent note, pointing out that its view incorporates just $1 trillion of the Biden plan.</p>\n<p>Indeed, Goldman Sachs upgraded its 2021 GDP forecast to 6.8% earlier this week because the Wall Street bank now assumes additional fiscal relief of $1.5 trillion, up from $1.1 trillion previously. If Goldman's prediction comes true, it would be the fastest annual GDP growth for the United States since 1989,according to the St. Louis Fed.</p>\n<p>The rosy GDP forecasts are well above what the Federal Reserve is calling for. In December, the Fed expected 2021 GDP growth of just 4.2% and said unemployment wouldn't slip below 4% until 2023.</p>\n<p><b>Double-dip recession averted</b></p>\n<p>The Fed tends to be conservative with its economic forecasts. And, crucially, the Fed forecast was released at a time when political dysfunction in DC was casting a shadow over the US economy.</p>\n<p>For months, Republicans and Democrats tried and failed to reach a deal on extending crucial unemployment and eviction benefits scheduled to lapse and providing more forgivable loans to small businesses. And then when a deal was finally reached, former President Donald Trump threatened to blow it up.</p>\n<p>At the last minute, Trump signed the $900 billion relief package into law, averting economic disaster.</p>\n<p>\"Without that, we would be in a double dip recession,\" said Zandi, the Moody's economist.</p>\n<p>Slammed by the pandemic, the US economy limped to the end of 2020 and started this year slowly. In December, employers cut jobs in for the first time since the spring. And the United States added just 49,000 jobs in January.</p>\n<p>Jobless claims remain alarmingly high. Another 793,000 Americans filed for first time unemployment benefits last week alone. For context, that is above the worst levels of the Great Recession.</p>\n<p><b>Vaccines to the rescue</b></p>\n<p>But there are glimmers of hope on the pandemic. Although Covid deaths remain unthinkably high, hospitalizations and cases have retreated.</p>\n<p>Critically, the rollout of coronavirus vaccines is accelerating. Out of a total of 66 million vaccines distributed, about 70% have been administered, according to Morgan Stanley.</p>\n<p>And Dr. Anthony Fauci, the nation's top infectious disease expert,told NBC News Thursday that the United States may be able to vaccinate most Americans by the middle or end of summer.</p>\n<p>All of this has allowed states including California, New York and New Jersey to relax health restrictions crushing restaurants and other small businesses.</p>\n<p>That's not to say the pandemic is over. In fact,one risk is that new Covid-19 variants force US states and cities to once again tighten health restrictions.</p>\n<p><b>Low-wage workers are still hurting badly</b></p>\n<p>Against this backdrop, many economists are urging Washington to push ahead with plans for aggressive fiscal stimulus.</p>\n<p>\"Foot flat on the accelerator, please,\" Zandi, the Moody's economist said. \"Policymaking 101 says err on the side of doing too much, rather than too little.\"</p>\n<p>Doing too little risks worsening America's inequality problem. That's because this recession, more than prior ones, disproportionately hurt low-income workers in hard-hit sectors such as restaurants, childcare and hospitality.</p>\n<p>Employment levels of low-wage workers (those making less than $27,000 per year) is still down more than 20%, according to the Opportunity Insights Economic tracker. By contrast, employment levels of those making more than $60,000 per year are above pre-crisis levels.</p>\n<p>\"Biden's team is unlikely to break out the champagne over reaching full employment if it isn't evident across income and racial groups,\" economists at Bank of America wrote in a report to clients.</p>\n<p>However, Danielle DiMartino Booth, a former Fed official who is now CEO of Quill Intelligence, worries the focus on providing income, instead of investing in infrastructure and reskilling workers, will make the country addicted to stimulus.</p>\n<p>\"The economy is going to turn into this dependent patient, always waiting for the next injection,\" Booth said.</p>\n<p><b>'Bring it on'</b></p>\n<p>Some economists, including former Treasury Secretary Larry Summers, have warned there is a risk that Washington overheats the economy by injecting too much support.</p>\n<p>\"You could have quite the inflation scare in the next few months that will test the bond market and the Fed,\" Booth said.</p>\n<p>And that in turn would spook the red-hot stock market.</p>\n<p>Fed watchers are moving up their timelines for when the central bank will be able to end its emergency policies.</p>\n<p>Citing \"signs of a firmer inflation outlook,\" Goldman Sachs now expects the Fed to start \"tapering\" its asset purchases in early 2022 and to raise interest rates in the first half of 2024.</p>\n<p>Zandi isn't losing sleep over inflation, mostly because the United States is far from full employment.</p>\n<p>\"It's a vastly overstated worry,\" he said. \"Bring it on. Our biggest problem for more than a decade has been low inflation. Higher inflation would be a high-class problem to have.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>With Biden going big, Wall Street economists are growing bullish on the US economy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWith Biden going big, Wall Street economists are growing bullish on the US economy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-16 18:03 GMT+8 <a href=https://edition.cnn.com/2021/02/11/economy/economy-jobs-biden-stimulus/index.html><strong>CNN Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New York (CNN Business) The Covid-ravaged American economy was on the verge of slipping into a double-dip recession at the end of 2020. The pandemic was intensifying,gridlock paralyzed Washington and ...</p>\n\n<a href=\"https://edition.cnn.com/2021/02/11/economy/economy-jobs-biden-stimulus/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://edition.cnn.com/2021/02/11/economy/economy-jobs-biden-stimulus/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108705396","content_text":"New York (CNN Business) The Covid-ravaged American economy was on the verge of slipping into a double-dip recession at the end of 2020. The pandemic was intensifying,gridlock paralyzed Washington and millions of families were about to lose crucial benefits.\nFast forward two months, and the economy is still struggling-- but confidence in the recovery is growing, rapidly.\nEconomists are swiftly upgrading their GDP and unemployment forecasts and pulling forward the date when the Federal Reserve will be able to lift rock-bottom interest rates. Goldman Sachs is predicting the US economy will grow at the fastest clip in more than three decades.\nThe renewed optimism is being driven by two major factors: the health crisis is easing and Uncle Sam is coming to the rescue with staggering amounts of aid-- hundreds of billions more than seemed to be in the cards just months ago.\nAfter supplying $4 trillion of relief last year, Washington is expected to pump in another $2 trillion of deficit-financed support in 2021, according to Moody's Analytics. That represents more than a quarter of annual US GDP.\n\"That is a lot of economic juice,\" Mark Zandi, chief economist at Moody's Analytics, told CNN Business.\nThe turning point happened last month when Democrats took narrow control of the US Senate by sweeping the runoff races in Georgia. That opened a path for President Joe Biden's $1.9 trillion American Rescue Plan, which features $1,400 stimulus checks, enhanced unemployment benefits and a $350 billion lifeline to state and local governments.\n'Summer mini-boom'\nBefore the Georgia elections, Zandi didn't think the US economy would return to full employment (a strong labor market with 4% unemployment) until the spring or summer of 2023. Now, he expects that achievement to happen next spring, echoing a forecast by Treasury Secretary Janet Yellen.\n\"Super-charged fiscal policy\" means the argument for the US economy growing faster than its peers \"seems to get stronger day-by-day,\" economists at Bank of America wrote in a recent report to clients.\nOxford Economics chief US economist Gregory Daco is calling for a \"summer mini-boom\" in the United States and 5.9% GDP growth in 2021.\nLikewise, Jefferies economists say \"explosive income growth (courtesy of fiscal stimulus) is likely to propel US GDP 6.4% higher this year and nearly 5% next year.\"\n\"If anything, our forecast might be too conservative,\" Jefferies told clients in a recent note, pointing out that its view incorporates just $1 trillion of the Biden plan.\nIndeed, Goldman Sachs upgraded its 2021 GDP forecast to 6.8% earlier this week because the Wall Street bank now assumes additional fiscal relief of $1.5 trillion, up from $1.1 trillion previously. If Goldman's prediction comes true, it would be the fastest annual GDP growth for the United States since 1989,according to the St. Louis Fed.\nThe rosy GDP forecasts are well above what the Federal Reserve is calling for. In December, the Fed expected 2021 GDP growth of just 4.2% and said unemployment wouldn't slip below 4% until 2023.\nDouble-dip recession averted\nThe Fed tends to be conservative with its economic forecasts. And, crucially, the Fed forecast was released at a time when political dysfunction in DC was casting a shadow over the US economy.\nFor months, Republicans and Democrats tried and failed to reach a deal on extending crucial unemployment and eviction benefits scheduled to lapse and providing more forgivable loans to small businesses. And then when a deal was finally reached, former President Donald Trump threatened to blow it up.\nAt the last minute, Trump signed the $900 billion relief package into law, averting economic disaster.\n\"Without that, we would be in a double dip recession,\" said Zandi, the Moody's economist.\nSlammed by the pandemic, the US economy limped to the end of 2020 and started this year slowly. In December, employers cut jobs in for the first time since the spring. And the United States added just 49,000 jobs in January.\nJobless claims remain alarmingly high. Another 793,000 Americans filed for first time unemployment benefits last week alone. For context, that is above the worst levels of the Great Recession.\nVaccines to the rescue\nBut there are glimmers of hope on the pandemic. Although Covid deaths remain unthinkably high, hospitalizations and cases have retreated.\nCritically, the rollout of coronavirus vaccines is accelerating. Out of a total of 66 million vaccines distributed, about 70% have been administered, according to Morgan Stanley.\nAnd Dr. Anthony Fauci, the nation's top infectious disease expert,told NBC News Thursday that the United States may be able to vaccinate most Americans by the middle or end of summer.\nAll of this has allowed states including California, New York and New Jersey to relax health restrictions crushing restaurants and other small businesses.\nThat's not to say the pandemic is over. In fact,one risk is that new Covid-19 variants force US states and cities to once again tighten health restrictions.\nLow-wage workers are still hurting badly\nAgainst this backdrop, many economists are urging Washington to push ahead with plans for aggressive fiscal stimulus.\n\"Foot flat on the accelerator, please,\" Zandi, the Moody's economist said. \"Policymaking 101 says err on the side of doing too much, rather than too little.\"\nDoing too little risks worsening America's inequality problem. That's because this recession, more than prior ones, disproportionately hurt low-income workers in hard-hit sectors such as restaurants, childcare and hospitality.\nEmployment levels of low-wage workers (those making less than $27,000 per year) is still down more than 20%, according to the Opportunity Insights Economic tracker. By contrast, employment levels of those making more than $60,000 per year are above pre-crisis levels.\n\"Biden's team is unlikely to break out the champagne over reaching full employment if it isn't evident across income and racial groups,\" economists at Bank of America wrote in a report to clients.\nHowever, Danielle DiMartino Booth, a former Fed official who is now CEO of Quill Intelligence, worries the focus on providing income, instead of investing in infrastructure and reskilling workers, will make the country addicted to stimulus.\n\"The economy is going to turn into this dependent patient, always waiting for the next injection,\" Booth said.\n'Bring it on'\nSome economists, including former Treasury Secretary Larry Summers, have warned there is a risk that Washington overheats the economy by injecting too much support.\n\"You could have quite the inflation scare in the next few months that will test the bond market and the Fed,\" Booth said.\nAnd that in turn would spook the red-hot stock market.\nFed watchers are moving up their timelines for when the central bank will be able to end its emergency policies.\nCiting \"signs of a firmer inflation outlook,\" Goldman Sachs now expects the Fed to start \"tapering\" its asset purchases in early 2022 and to raise interest rates in the first half of 2024.\nZandi isn't losing sleep over inflation, mostly because the United States is far from full employment.\n\"It's a vastly overstated worry,\" he said. \"Bring it on. Our biggest problem for more than a decade has been low inflation. Higher inflation would be a high-class problem to have.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":361,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":314536981,"gmtCreate":1612361725943,"gmtModify":1703760838480,"author":{"id":"3563929170003666","authorId":"3563929170003666","name":"HongWang","avatar":"https://static.tigerbbs.com/98c4dd0e0d1f9e2e40e2885b36ade4a0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[开心] ","listText":"[开心] ","text":"[开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/314536981","repostId":"2108275621","repostType":4,"isVote":1,"tweetType":1,"viewCount":317,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":314594334,"gmtCreate":1612361294728,"gmtModify":1703760828492,"author":{"id":"3563929170003666","authorId":"3563929170003666","name":"HongWang","avatar":"https://static.tigerbbs.com/98c4dd0e0d1f9e2e40e2885b36ade4a0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[微笑] ","listText":"[微笑] ","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/314594334","repostId":"2108876804","repostType":4,"repost":{"id":"2108876804","pubTimestamp":1612348872,"share":"https://www.laohu8.com/m/news/2108876804?lang=&edition=full","pubTime":"2021-02-03 18:41","market":"sg","language":"en","title":"Neo Group to acquire 51% stake in snack maker","url":"https://stock-news.laohu8.com/highlight/detail?id=2108876804","media":"businesstimes","summary":"\n \n CATALIST-LISTED food caterer Neo Group is acquiring a 51 per cent stake in local snack manufacturer Royale International Food Industries (RIFI) for S$1.02 million in cash, it said in an exchange filing on Wednesday.\n \n","content":"<div>\n<p>CATALIST-LISTED food caterer Neo Group is acquiring a 51 per cent stake in local snack manufacturer Royale International Food Industries (RIFI) for S$1.02 million in cash, it said in an exchange ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/neo-group-to-acquire-51-stake-in-snack-maker\">Web Link</a>\n\n</div>\n","source":"bustime_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neo Group to acquire 51% stake in snack maker</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeo Group to acquire 51% stake in snack maker\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-03 18:41 GMT+8 <a href=https://www.businesstimes.com.sg/companies-markets/neo-group-to-acquire-51-stake-in-snack-maker><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CATALIST-LISTED food caterer Neo Group is acquiring a 51 per cent stake in local snack manufacturer Royale International Food Industries (RIFI) for S$1.02 million in cash, it said in an exchange ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/neo-group-to-acquire-51-stake-in-snack-maker\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.businesstimes.com.sg/companies-markets/neo-group-to-acquire-51-stake-in-snack-maker","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2108876804","content_text":"CATALIST-LISTED food caterer Neo Group is acquiring a 51 per cent stake in local snack manufacturer Royale International Food Industries (RIFI) for S$1.02 million in cash, it said in an exchange filing on Wednesday.\nThe proposed acquisition is being carried out via wholly-owned subsidiary Thong Siek Global, with the consideration financed by internal cash resources and/or bank borrowings.\nNeo Group's chairman and chief executive officer Neo Kah Kiat said the move is a \"strategic fit\" for its food-manufacturing business, and the diversification into snack food products will broaden the group's revenue stream, with the added benefit of expanding into new overseas markets.\nRIFI is principally engaged in the manufacture of snacks under its flagship brand, Crusty's, with a selection of ready-to-eat products such as potato chips, fish skin and soy-based snacks. Neo Group said these snacks are available locally in Singapore, and also exported and sold in overseas markets such as Australia, China, the US and Malaysia.\nMr Neo said: \"In line with our growth strategies, we intend to actively expand our product offerings to cater to different market segments, to meet changing consumer demand and capture growth opportunities in snacks and ready-to-eat products.\n\"This earnings-accretive acquisition will also allow us to create new income streams, drive our export sales to new and existing markets worldwide, tapping both parties' well-established network across over 30 countries globally.\"\nNeo Group said the proposed acquisition is not expected to have any material impact on the group's consolidated net tangible assets or earnings per share for its current financial year ending March 31.\nShares of Neo Group fell one per cent or 0.5 Singapore cent on Wednesday to close at 52.5 cents before the announcement.","news_type":1},"isVote":1,"tweetType":1,"viewCount":543,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":867188655,"gmtCreate":1633226568725,"gmtModify":1633226570462,"author":{"id":"3563929170003666","authorId":"3563929170003666","name":"HongWang","avatar":"https://static.tigerbbs.com/98c4dd0e0d1f9e2e40e2885b36ade4a0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/867188655","repostId":"2172643049","repostType":4,"repost":{"id":"2172643049","pubTimestamp":1633222044,"share":"https://www.laohu8.com/m/news/2172643049?lang=&edition=full","pubTime":"2021-10-03 08:47","market":"us","language":"en","title":"2 Ridiculously Cheap Growth Stocks to Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2172643049","media":"Motley Fool","summary":"Though these companies have recorded solid financials of late, investors are overlooking them.","content":"<p>Growth stocks can sometimes trade at inflated valuations because of their attractive long-term potential. So if you get the opportunity to invest in a growth stock that isn't trading at a premium but rather at a discount, you should definitely consider adding it to your portfolio.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> unloved growth stocks that trade at low multiples of future earnings and look incredibly cheap right now are <b>Bristol Myers Squibb</b> (NYSE:BMY) and <b>ViacomCBS </b>(NASDAQ:VIAC).<img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>1. Bristol Myers Squibb</h2>\n<p>Healthcare giant Bristol Myers Squibb is a stock that investors could easily be overlooking right now. From afar, its financials look horrible. For the trailing 12 months, the company incurred a net loss of $5 billion. So investors relying on stock screeners to try and find good buys could easily overlook Bristol Myers -- and they have. Year to date, shares of the healthcare stock are down about 2% while the <b>S&P 500</b> has soared 16%.</p>\n<p>But investors who dig a little deeper will find a slightly different story. The huge loss is in fact due to a massive research and development charge of more than $11 billion that the company incurred for its acquisition of MyoKardia, a clinical-stage biopharmaceutical company that develops cardiovascular medicine. That negatively impacted the fourth quarter of last year and is still impacting the trailing 12-month numbers.</p>\n<p>In the past two quarters, however, the company has been firmly in the black. Through the first six months of 2021, Bristol Myers' revenue of $22.8 billion has risen 9% year over year, and its net earnings have flipped from a $846 million loss in 2020 to a $3.1 billion profit.</p>\n<p>Meanwhile, with free cash flow of $11.7 billion over the past four quarters, its dividend also looks rock-solid. The company has paid out $4.2 billion during that time while also making stock repurchases of $4.5 billion. This serves as further proof that accounting income alone can't be relied on to assess the health of a company's operations. Cash flow is arguably a much more important indicator than net income -- and by that metric, Bristol Myers is doing just fine.</p>\n<p>So a closer look at Bristol Myers suggests the company is a much safer buy than its numbers may appear at first glance. A forward price-to-earnings (P/E) ratio can be useful for companies when a bad quarter or two have weighed on their numbers. And by that measure, Bristol Myers only trades at a P/E of 8 — incredibly cheap compared to other healthcare stocks, such as <b>Merck</b> (NYSE:MRK) and <b>Amgen </b>(NASDAQ:AMGN), which both trade at about 13 times their future profits.</p>\n<p>Finally, there's the 3.3% dividend yield, which is more than twice as much as the S&P 500's 1.3%. Whether you're a growth investor or love a good dividend, this is an underrated healthcare stock that should be on your radar.</p>\n<h2>2. ViacomCBS</h2>\n<p>Another stock that's trading at a low valuation is ViacomCBS. At a forward P/E multiple of just 10, it's nowhere near the premium that investors are paying for other companies in the entertainment and streaming business, such as <b>Netflix</b> (NASDAQ:NFLX) and <b>Walt Disney </b>(NYSE:DIS) -- trading at 56 and 70 times their forward profits, respectively.</p>\n<p>Admittedly, ViacomCBS' Paramount+ streaming service isn't as popular, and that could be a reason investors aren't giving the stock as much of a chance. Overall, the company has a total of 42 million global streaming subscribers (including Paramount+ and other smaller services such as Pluto TV). By comparison, Netflix has more than 200 million subscribers while Disney+ now has 116 million.</p>\n<p>But Paramount+ doesn't have to be the top streaming service for ViacomCBS to be an attractive buy. In its latest quarter ended June 30, the company reported that streaming revenue grew 92% to $983 million from the year-ago period and advertising revenue rose 24% to $2.1 billion.</p>\n<p>The lone blemish for the company was its \"licensing and other\" segment, which fell 36% to $1.2 billion -- hurt by the absence of theatrical releases during the pandemic. That kept the company's sales growth relatively modest last quarter, rising 8% to $6.6 billion. However, as the economy continues to recover from the pandemic, those numbers should get stronger.</p>\n<p>Meanwhile, ViacomCBS also offers investors an above-average dividend yield of 2.4%. And with free cash of $2.6 billion over the past 12 months, it is generating more than enough to cover the $601 million in dividends it paid out during that time.</p>\n<p>So, while Paramount+ may be an afterthought for some investors looking to go into top streaming stocks, that in fact could be an opportunity. ViacomCBS shares still fly under the radar -- up just 8% this year. As subscribers continue to increase and revenues improve, it may just be a matter of time before the stock takes off.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Ridiculously Cheap Growth Stocks to Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Ridiculously Cheap Growth Stocks to Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-03 08:47 GMT+8 <a href=https://www.fool.com/investing/2021/10/02/2-ridiculously-cheap-growth-stocks-to-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks can sometimes trade at inflated valuations because of their attractive long-term potential. So if you get the opportunity to invest in a growth stock that isn't trading at a premium but ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/02/2-ridiculously-cheap-growth-stocks-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QNETCN":"纳斯达克中美互联网老虎指数","NFLX":"奈飞"},"source_url":"https://www.fool.com/investing/2021/10/02/2-ridiculously-cheap-growth-stocks-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2172643049","content_text":"Growth stocks can sometimes trade at inflated valuations because of their attractive long-term potential. So if you get the opportunity to invest in a growth stock that isn't trading at a premium but rather at a discount, you should definitely consider adding it to your portfolio.\nTwo unloved growth stocks that trade at low multiples of future earnings and look incredibly cheap right now are Bristol Myers Squibb (NYSE:BMY) and ViacomCBS (NASDAQ:VIAC).\nImage source: Getty Images.\n1. Bristol Myers Squibb\nHealthcare giant Bristol Myers Squibb is a stock that investors could easily be overlooking right now. From afar, its financials look horrible. For the trailing 12 months, the company incurred a net loss of $5 billion. So investors relying on stock screeners to try and find good buys could easily overlook Bristol Myers -- and they have. Year to date, shares of the healthcare stock are down about 2% while the S&P 500 has soared 16%.\nBut investors who dig a little deeper will find a slightly different story. The huge loss is in fact due to a massive research and development charge of more than $11 billion that the company incurred for its acquisition of MyoKardia, a clinical-stage biopharmaceutical company that develops cardiovascular medicine. That negatively impacted the fourth quarter of last year and is still impacting the trailing 12-month numbers.\nIn the past two quarters, however, the company has been firmly in the black. Through the first six months of 2021, Bristol Myers' revenue of $22.8 billion has risen 9% year over year, and its net earnings have flipped from a $846 million loss in 2020 to a $3.1 billion profit.\nMeanwhile, with free cash flow of $11.7 billion over the past four quarters, its dividend also looks rock-solid. The company has paid out $4.2 billion during that time while also making stock repurchases of $4.5 billion. This serves as further proof that accounting income alone can't be relied on to assess the health of a company's operations. Cash flow is arguably a much more important indicator than net income -- and by that metric, Bristol Myers is doing just fine.\nSo a closer look at Bristol Myers suggests the company is a much safer buy than its numbers may appear at first glance. A forward price-to-earnings (P/E) ratio can be useful for companies when a bad quarter or two have weighed on their numbers. And by that measure, Bristol Myers only trades at a P/E of 8 — incredibly cheap compared to other healthcare stocks, such as Merck (NYSE:MRK) and Amgen (NASDAQ:AMGN), which both trade at about 13 times their future profits.\nFinally, there's the 3.3% dividend yield, which is more than twice as much as the S&P 500's 1.3%. Whether you're a growth investor or love a good dividend, this is an underrated healthcare stock that should be on your radar.\n2. ViacomCBS\nAnother stock that's trading at a low valuation is ViacomCBS. At a forward P/E multiple of just 10, it's nowhere near the premium that investors are paying for other companies in the entertainment and streaming business, such as Netflix (NASDAQ:NFLX) and Walt Disney (NYSE:DIS) -- trading at 56 and 70 times their forward profits, respectively.\nAdmittedly, ViacomCBS' Paramount+ streaming service isn't as popular, and that could be a reason investors aren't giving the stock as much of a chance. Overall, the company has a total of 42 million global streaming subscribers (including Paramount+ and other smaller services such as Pluto TV). By comparison, Netflix has more than 200 million subscribers while Disney+ now has 116 million.\nBut Paramount+ doesn't have to be the top streaming service for ViacomCBS to be an attractive buy. In its latest quarter ended June 30, the company reported that streaming revenue grew 92% to $983 million from the year-ago period and advertising revenue rose 24% to $2.1 billion.\nThe lone blemish for the company was its \"licensing and other\" segment, which fell 36% to $1.2 billion -- hurt by the absence of theatrical releases during the pandemic. That kept the company's sales growth relatively modest last quarter, rising 8% to $6.6 billion. However, as the economy continues to recover from the pandemic, those numbers should get stronger.\nMeanwhile, ViacomCBS also offers investors an above-average dividend yield of 2.4%. And with free cash of $2.6 billion over the past 12 months, it is generating more than enough to cover the $601 million in dividends it paid out during that time.\nSo, while Paramount+ may be an afterthought for some investors looking to go into top streaming stocks, that in fact could be an opportunity. ViacomCBS shares still fly under the radar -- up just 8% this year. As subscribers continue to increase and revenues improve, it may just be a matter of time before the stock takes off.","news_type":1},"isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":350183257,"gmtCreate":1616166209179,"gmtModify":1634526897949,"author":{"id":"3563929170003666","authorId":"3563929170003666","name":"HongWang","avatar":"https://static.tigerbbs.com/98c4dd0e0d1f9e2e40e2885b36ade4a0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[微笑] ","listText":"[微笑] ","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/350183257","repostId":"1190757715","repostType":4,"repost":{"id":"1190757715","pubTimestamp":1616161968,"share":"https://www.laohu8.com/m/news/1190757715?lang=&edition=full","pubTime":"2021-03-19 21:52","market":"us","language":"en","title":"1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should","url":"https://stock-news.laohu8.com/highlight/detail?id=1190757715","media":"Motley Fool","summary":"It might be a surprise to find out that two investors with virtually opposite approaches -- one who ","content":"<p>It might be a surprise to find out that two investors with virtually opposite approaches -- one who invests in large, cheap, iconic companies and the other who rose to fame on the heels of her outlandishly bullish (and accurate) predictions about \"overvalued\" stocks -- would have the same company in their portfolios. Perhaps the bigger surprise is the stock you might expect them to both own that they don't. Let's take a look at the two companies in question and what these successful investors must see.</p><p><b>The surprising stock they both own</b></p><p>First, it's doubtful that Warren Buffett actually bought<b>Snowflake</b>(NYSE:SNOW), the cloud data warehouse-as-a-service company. In recent years, lieutenants Todd Combs and Ted Weschler have been making more of the investment decisions, and the $750 million in stock<b>BerkshireHathaway</b>(NYSE:BRK.A)(NYSE:BRK.B)purchased before theinitial public offering (IPO)certainly doesn't match the investment style of the legendary nonagenarian. In fact, Buffett hasn't bought an IPO since<b>Ford</b> in 1956. The company does fit the style of Cathie Wood at ARK Invest, a global asset management company focused on disruptive innovation. That said, Snowflake is putting up numbers that would get any investor's attention.</p><p>The company recently reported its full fiscal year earnings, and the growth was jaw-dropping. Fourth-quarter revenue of $178 million was up 116% year over year. Topping that, remaining performance obligations, what customers have signed on to buy, was up 213% over the same point last year. The company has 77 customers that spend more than $1 million per year. That number is up from 65 just three months earlier. Management is projecting between 92% and 96% revenue growth for the current year. Snowflake posted an operating margin of negative 92%. Losing money never sounds good, but that is closer to profitability than the negative 135% for the year ending January 2020 or the negative 192% in 2019. If the company really wanted to turn a profit it could just curb its spending on sales and marketing.</p><p>It may not be a typical Buffett stock, but Snowflake definitely fits the mold of Wood's investments. The ARK founder has become synonymous with innovation, building a portfolio around futuristic themes such as genomics, space exploration, mobility-as-a-service, and the next-generation internet. It's the last theme, encompassing artificial intelligence and cloud computing, where Snowflake fits. The company's pay-as-you-consume, real-time access to data and analytical tools is a giant leap forward compared to the slow, bogged-down daily or weekly updates companies have long come to accept with managing their internal data warehouses.</p><p>Another stock in ARK's portfolio touches both the data-related and genomic revolution strategy. Based on his other holdings, it's actually surprising Buffett doesn't own it too.</p><p><b>The surprising stock they don't both own</b></p><p>The Oracle of Omaha has been buying up the stocks of pharmaceutical companies in the past year. In the third quarter of 2020 he added shares of<b>Pfizer</b>(NYSE:PFE),<b>AbbVie</b>(NYSE:ABBV),<b>Merck</b>(NYSE:MRK), and<b>BristolMyersSquibb</b>(NYSE:BMY). Every member of that group gives investors between 3% and 5% in dividends annually. Other than Bristol Myers, they all hover around a $200 billion market cap as well, and Bristol Myers is nearly as large at $136 billion. Similarly,<b>Novartis</b>(NYSE:NVS)is a $211 billion company yielding 3.8%. Perhaps the reason Buffett hasn't bought this big pharma stock is that it is a Swiss company. It turns out, Buffett favors American brands in food, cola, and apparently drugmakers.</p><p>Novartis did catch the eye of Wood, thanks to its work toward developing a leading digital and data science platform for drug discovery. Although it isn't a pure play on any of ARK's strategies, Wood considers it a deep value pick, to be held through a bull market and then sold in times of volatility to add to higher-conviction growth names that get beaten down.</p><p><b>Portfolio juxtaposition</b></p><p>It may be counterintuitive for an investor who prides himself on unemotional investing to buy into one of the hottest IPOs of last year, but once Snowflake started trading, the investment doubled almost immediately. Similarly, few would think someone famous for a $4,000 price target on<b>Tesla</b>and presentations that literally map out the future of entire industries would own a nearly 4% dividend paying pharmaceutical company with no growth. However, there is a great lesson in these examples.</p><p>Don't settle for the labels Wall Street places on companies or investors. Value and growth are just words. Investors may have tendencies that define them in the public eye, but that oversimplification may obscure the characteristics that draw their interest in an investment. Although Buffett likely didn't buy shares of Snowflake, it may have been the customer loyalty, leadership team, and consistent march toward profitability that made Combs or Weschler comfortable buying Snowflake shares. Wood may have a lot of fast-growing companies that don't make a profit, but it's the innovation that compels her to invest, not just growth rate. In the case of Novartis, innovation came in the form of a mega-cap pharmaceutical company.</p><p>Instead of focusing on the labels Wall Street slaps on a company or following Warren Buffett or Cathie Wood into the stock, try to identify the characteristics of the business that they find compelling. Try approaching the company as if you were going to inherit it, learning how dedicated customers are, where money gets spent to attract new ones, or what advantages it has over competitors. These answers will lead to a more informed investment decision and better outcomes over time.</p><p>It turns out, both Snowflake and Novartis are compelling to different types of investors for a variety of reasons. Exploring those reasons can teach us a lot more about investing than focusing solely on who owns them. The more we know about a company, the easier it is to figure out whether the nextsell-off is something to fear or a great opportunity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-19 21:52 GMT+8 <a href=https://www.fool.com/investing/2021/03/19/1-stock-warren-buffett-and-cathie-wood-have-in-com/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It might be a surprise to find out that two investors with virtually opposite approaches -- one who invests in large, cheap, iconic companies and the other who rose to fame on the heels of her ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/19/1-stock-warren-buffett-and-cathie-wood-have-in-com/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/19/1-stock-warren-buffett-and-cathie-wood-have-in-com/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190757715","content_text":"It might be a surprise to find out that two investors with virtually opposite approaches -- one who invests in large, cheap, iconic companies and the other who rose to fame on the heels of her outlandishly bullish (and accurate) predictions about \"overvalued\" stocks -- would have the same company in their portfolios. Perhaps the bigger surprise is the stock you might expect them to both own that they don't. Let's take a look at the two companies in question and what these successful investors must see.The surprising stock they both ownFirst, it's doubtful that Warren Buffett actually boughtSnowflake(NYSE:SNOW), the cloud data warehouse-as-a-service company. In recent years, lieutenants Todd Combs and Ted Weschler have been making more of the investment decisions, and the $750 million in stockBerkshireHathaway(NYSE:BRK.A)(NYSE:BRK.B)purchased before theinitial public offering (IPO)certainly doesn't match the investment style of the legendary nonagenarian. In fact, Buffett hasn't bought an IPO sinceFord in 1956. The company does fit the style of Cathie Wood at ARK Invest, a global asset management company focused on disruptive innovation. That said, Snowflake is putting up numbers that would get any investor's attention.The company recently reported its full fiscal year earnings, and the growth was jaw-dropping. Fourth-quarter revenue of $178 million was up 116% year over year. Topping that, remaining performance obligations, what customers have signed on to buy, was up 213% over the same point last year. The company has 77 customers that spend more than $1 million per year. That number is up from 65 just three months earlier. Management is projecting between 92% and 96% revenue growth for the current year. Snowflake posted an operating margin of negative 92%. Losing money never sounds good, but that is closer to profitability than the negative 135% for the year ending January 2020 or the negative 192% in 2019. If the company really wanted to turn a profit it could just curb its spending on sales and marketing.It may not be a typical Buffett stock, but Snowflake definitely fits the mold of Wood's investments. The ARK founder has become synonymous with innovation, building a portfolio around futuristic themes such as genomics, space exploration, mobility-as-a-service, and the next-generation internet. It's the last theme, encompassing artificial intelligence and cloud computing, where Snowflake fits. The company's pay-as-you-consume, real-time access to data and analytical tools is a giant leap forward compared to the slow, bogged-down daily or weekly updates companies have long come to accept with managing their internal data warehouses.Another stock in ARK's portfolio touches both the data-related and genomic revolution strategy. Based on his other holdings, it's actually surprising Buffett doesn't own it too.The surprising stock they don't both ownThe Oracle of Omaha has been buying up the stocks of pharmaceutical companies in the past year. In the third quarter of 2020 he added shares ofPfizer(NYSE:PFE),AbbVie(NYSE:ABBV),Merck(NYSE:MRK), andBristolMyersSquibb(NYSE:BMY). Every member of that group gives investors between 3% and 5% in dividends annually. Other than Bristol Myers, they all hover around a $200 billion market cap as well, and Bristol Myers is nearly as large at $136 billion. Similarly,Novartis(NYSE:NVS)is a $211 billion company yielding 3.8%. Perhaps the reason Buffett hasn't bought this big pharma stock is that it is a Swiss company. It turns out, Buffett favors American brands in food, cola, and apparently drugmakers.Novartis did catch the eye of Wood, thanks to its work toward developing a leading digital and data science platform for drug discovery. Although it isn't a pure play on any of ARK's strategies, Wood considers it a deep value pick, to be held through a bull market and then sold in times of volatility to add to higher-conviction growth names that get beaten down.Portfolio juxtapositionIt may be counterintuitive for an investor who prides himself on unemotional investing to buy into one of the hottest IPOs of last year, but once Snowflake started trading, the investment doubled almost immediately. Similarly, few would think someone famous for a $4,000 price target onTeslaand presentations that literally map out the future of entire industries would own a nearly 4% dividend paying pharmaceutical company with no growth. However, there is a great lesson in these examples.Don't settle for the labels Wall Street places on companies or investors. Value and growth are just words. Investors may have tendencies that define them in the public eye, but that oversimplification may obscure the characteristics that draw their interest in an investment. Although Buffett likely didn't buy shares of Snowflake, it may have been the customer loyalty, leadership team, and consistent march toward profitability that made Combs or Weschler comfortable buying Snowflake shares. Wood may have a lot of fast-growing companies that don't make a profit, but it's the innovation that compels her to invest, not just growth rate. In the case of Novartis, innovation came in the form of a mega-cap pharmaceutical company.Instead of focusing on the labels Wall Street slaps on a company or following Warren Buffett or Cathie Wood into the stock, try to identify the characteristics of the business that they find compelling. Try approaching the company as if you were going to inherit it, learning how dedicated customers are, where money gets spent to attract new ones, or what advantages it has over competitors. These answers will lead to a more informed investment decision and better outcomes over time.It turns out, both Snowflake and Novartis are compelling to different types of investors for a variety of reasons. Exploring those reasons can teach us a lot more about investing than focusing solely on who owns them. The more we know about a company, the easier it is to figure out whether the nextsell-off is something to fear or a great opportunity.","news_type":1},"isVote":1,"tweetType":1,"viewCount":320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":382408375,"gmtCreate":1613471848597,"gmtModify":1634553544937,"author":{"id":"3563929170003666","authorId":"3563929170003666","name":"HongWang","avatar":"https://static.tigerbbs.com/98c4dd0e0d1f9e2e40e2885b36ade4a0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[得意] ","listText":"[得意] ","text":"[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/382408375","repostId":"1108705396","repostType":4,"repost":{"id":"1108705396","pubTimestamp":1613469786,"share":"https://www.laohu8.com/m/news/1108705396?lang=&edition=full","pubTime":"2021-02-16 18:03","market":"us","language":"en","title":"With Biden going big, Wall Street economists are growing bullish on the US economy","url":"https://stock-news.laohu8.com/highlight/detail?id=1108705396","media":"CNN Business","summary":"New York (CNN Business) The Covid-ravaged American economy was on the verge of slipping into a doubl","content":"<p><b>New York (CNN Business) </b>The Covid-ravaged American economy was on the verge of slipping into a double-dip recession at the end of 2020. The pandemic was intensifying,gridlock paralyzed Washington and millions of families were about to lose crucial benefits.</p>\n<p>Fast forward two months, and the economy is still struggling-- but confidence in the recovery is growing, rapidly.</p>\n<p>Economists are swiftly upgrading their GDP and unemployment forecasts and pulling forward the date when the Federal Reserve will be able to lift rock-bottom interest rates. Goldman Sachs is predicting the US economy will grow at the fastest clip in more than three decades.</p>\n<p>The renewed optimism is being driven by two major factors: the health crisis is easing and Uncle Sam is coming to the rescue with staggering amounts of aid-- hundreds of billions more than seemed to be in the cards just months ago.</p>\n<p>After supplying $4 trillion of relief last year, Washington is expected to pump in another $2 trillion of deficit-financed support in 2021, according to Moody's Analytics. That represents more than a quarter of annual US GDP.</p>\n<p>\"That is a lot of economic juice,\" Mark Zandi, chief economist at Moody's Analytics, told CNN Business.</p>\n<p>The turning point happened last month when Democrats took narrow control of the US Senate by sweeping the runoff races in Georgia. That opened a path for President Joe Biden's $1.9 trillion American Rescue Plan, which features $1,400 stimulus checks, enhanced unemployment benefits and a $350 billion lifeline to state and local governments.</p>\n<p><b>'Summer mini-boom'</b></p>\n<p>Before the Georgia elections, Zandi didn't think the US economy would return to full employment (a strong labor market with 4% unemployment) until the spring or summer of 2023. Now, he expects that achievement to happen next spring, echoing a forecast by Treasury Secretary Janet Yellen.</p>\n<p>\"Super-charged fiscal policy\" means the argument for the US economy growing faster than its peers \"seems to get stronger day-by-day,\" economists at Bank of America wrote in a recent report to clients.</p>\n<p>Oxford Economics chief US economist Gregory Daco is calling for a \"summer mini-boom\" in the United States and 5.9% GDP growth in 2021.</p>\n<p>Likewise, Jefferies economists say \"explosive income growth (courtesy of fiscal stimulus) is likely to propel US GDP 6.4% higher this year and nearly 5% next year.\"</p>\n<p>\"If anything, our forecast might be too conservative,\" Jefferies told clients in a recent note, pointing out that its view incorporates just $1 trillion of the Biden plan.</p>\n<p>Indeed, Goldman Sachs upgraded its 2021 GDP forecast to 6.8% earlier this week because the Wall Street bank now assumes additional fiscal relief of $1.5 trillion, up from $1.1 trillion previously. If Goldman's prediction comes true, it would be the fastest annual GDP growth for the United States since 1989,according to the St. Louis Fed.</p>\n<p>The rosy GDP forecasts are well above what the Federal Reserve is calling for. In December, the Fed expected 2021 GDP growth of just 4.2% and said unemployment wouldn't slip below 4% until 2023.</p>\n<p><b>Double-dip recession averted</b></p>\n<p>The Fed tends to be conservative with its economic forecasts. And, crucially, the Fed forecast was released at a time when political dysfunction in DC was casting a shadow over the US economy.</p>\n<p>For months, Republicans and Democrats tried and failed to reach a deal on extending crucial unemployment and eviction benefits scheduled to lapse and providing more forgivable loans to small businesses. And then when a deal was finally reached, former President Donald Trump threatened to blow it up.</p>\n<p>At the last minute, Trump signed the $900 billion relief package into law, averting economic disaster.</p>\n<p>\"Without that, we would be in a double dip recession,\" said Zandi, the Moody's economist.</p>\n<p>Slammed by the pandemic, the US economy limped to the end of 2020 and started this year slowly. In December, employers cut jobs in for the first time since the spring. And the United States added just 49,000 jobs in January.</p>\n<p>Jobless claims remain alarmingly high. Another 793,000 Americans filed for first time unemployment benefits last week alone. For context, that is above the worst levels of the Great Recession.</p>\n<p><b>Vaccines to the rescue</b></p>\n<p>But there are glimmers of hope on the pandemic. Although Covid deaths remain unthinkably high, hospitalizations and cases have retreated.</p>\n<p>Critically, the rollout of coronavirus vaccines is accelerating. Out of a total of 66 million vaccines distributed, about 70% have been administered, according to Morgan Stanley.</p>\n<p>And Dr. Anthony Fauci, the nation's top infectious disease expert,told NBC News Thursday that the United States may be able to vaccinate most Americans by the middle or end of summer.</p>\n<p>All of this has allowed states including California, New York and New Jersey to relax health restrictions crushing restaurants and other small businesses.</p>\n<p>That's not to say the pandemic is over. In fact,one risk is that new Covid-19 variants force US states and cities to once again tighten health restrictions.</p>\n<p><b>Low-wage workers are still hurting badly</b></p>\n<p>Against this backdrop, many economists are urging Washington to push ahead with plans for aggressive fiscal stimulus.</p>\n<p>\"Foot flat on the accelerator, please,\" Zandi, the Moody's economist said. \"Policymaking 101 says err on the side of doing too much, rather than too little.\"</p>\n<p>Doing too little risks worsening America's inequality problem. That's because this recession, more than prior ones, disproportionately hurt low-income workers in hard-hit sectors such as restaurants, childcare and hospitality.</p>\n<p>Employment levels of low-wage workers (those making less than $27,000 per year) is still down more than 20%, according to the Opportunity Insights Economic tracker. By contrast, employment levels of those making more than $60,000 per year are above pre-crisis levels.</p>\n<p>\"Biden's team is unlikely to break out the champagne over reaching full employment if it isn't evident across income and racial groups,\" economists at Bank of America wrote in a report to clients.</p>\n<p>However, Danielle DiMartino Booth, a former Fed official who is now CEO of Quill Intelligence, worries the focus on providing income, instead of investing in infrastructure and reskilling workers, will make the country addicted to stimulus.</p>\n<p>\"The economy is going to turn into this dependent patient, always waiting for the next injection,\" Booth said.</p>\n<p><b>'Bring it on'</b></p>\n<p>Some economists, including former Treasury Secretary Larry Summers, have warned there is a risk that Washington overheats the economy by injecting too much support.</p>\n<p>\"You could have quite the inflation scare in the next few months that will test the bond market and the Fed,\" Booth said.</p>\n<p>And that in turn would spook the red-hot stock market.</p>\n<p>Fed watchers are moving up their timelines for when the central bank will be able to end its emergency policies.</p>\n<p>Citing \"signs of a firmer inflation outlook,\" Goldman Sachs now expects the Fed to start \"tapering\" its asset purchases in early 2022 and to raise interest rates in the first half of 2024.</p>\n<p>Zandi isn't losing sleep over inflation, mostly because the United States is far from full employment.</p>\n<p>\"It's a vastly overstated worry,\" he said. \"Bring it on. Our biggest problem for more than a decade has been low inflation. Higher inflation would be a high-class problem to have.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>With Biden going big, Wall Street economists are growing bullish on the US economy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWith Biden going big, Wall Street economists are growing bullish on the US economy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-16 18:03 GMT+8 <a href=https://edition.cnn.com/2021/02/11/economy/economy-jobs-biden-stimulus/index.html><strong>CNN Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New York (CNN Business) The Covid-ravaged American economy was on the verge of slipping into a double-dip recession at the end of 2020. The pandemic was intensifying,gridlock paralyzed Washington and ...</p>\n\n<a href=\"https://edition.cnn.com/2021/02/11/economy/economy-jobs-biden-stimulus/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://edition.cnn.com/2021/02/11/economy/economy-jobs-biden-stimulus/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108705396","content_text":"New York (CNN Business) The Covid-ravaged American economy was on the verge of slipping into a double-dip recession at the end of 2020. The pandemic was intensifying,gridlock paralyzed Washington and millions of families were about to lose crucial benefits.\nFast forward two months, and the economy is still struggling-- but confidence in the recovery is growing, rapidly.\nEconomists are swiftly upgrading their GDP and unemployment forecasts and pulling forward the date when the Federal Reserve will be able to lift rock-bottom interest rates. Goldman Sachs is predicting the US economy will grow at the fastest clip in more than three decades.\nThe renewed optimism is being driven by two major factors: the health crisis is easing and Uncle Sam is coming to the rescue with staggering amounts of aid-- hundreds of billions more than seemed to be in the cards just months ago.\nAfter supplying $4 trillion of relief last year, Washington is expected to pump in another $2 trillion of deficit-financed support in 2021, according to Moody's Analytics. That represents more than a quarter of annual US GDP.\n\"That is a lot of economic juice,\" Mark Zandi, chief economist at Moody's Analytics, told CNN Business.\nThe turning point happened last month when Democrats took narrow control of the US Senate by sweeping the runoff races in Georgia. That opened a path for President Joe Biden's $1.9 trillion American Rescue Plan, which features $1,400 stimulus checks, enhanced unemployment benefits and a $350 billion lifeline to state and local governments.\n'Summer mini-boom'\nBefore the Georgia elections, Zandi didn't think the US economy would return to full employment (a strong labor market with 4% unemployment) until the spring or summer of 2023. Now, he expects that achievement to happen next spring, echoing a forecast by Treasury Secretary Janet Yellen.\n\"Super-charged fiscal policy\" means the argument for the US economy growing faster than its peers \"seems to get stronger day-by-day,\" economists at Bank of America wrote in a recent report to clients.\nOxford Economics chief US economist Gregory Daco is calling for a \"summer mini-boom\" in the United States and 5.9% GDP growth in 2021.\nLikewise, Jefferies economists say \"explosive income growth (courtesy of fiscal stimulus) is likely to propel US GDP 6.4% higher this year and nearly 5% next year.\"\n\"If anything, our forecast might be too conservative,\" Jefferies told clients in a recent note, pointing out that its view incorporates just $1 trillion of the Biden plan.\nIndeed, Goldman Sachs upgraded its 2021 GDP forecast to 6.8% earlier this week because the Wall Street bank now assumes additional fiscal relief of $1.5 trillion, up from $1.1 trillion previously. If Goldman's prediction comes true, it would be the fastest annual GDP growth for the United States since 1989,according to the St. Louis Fed.\nThe rosy GDP forecasts are well above what the Federal Reserve is calling for. In December, the Fed expected 2021 GDP growth of just 4.2% and said unemployment wouldn't slip below 4% until 2023.\nDouble-dip recession averted\nThe Fed tends to be conservative with its economic forecasts. And, crucially, the Fed forecast was released at a time when political dysfunction in DC was casting a shadow over the US economy.\nFor months, Republicans and Democrats tried and failed to reach a deal on extending crucial unemployment and eviction benefits scheduled to lapse and providing more forgivable loans to small businesses. And then when a deal was finally reached, former President Donald Trump threatened to blow it up.\nAt the last minute, Trump signed the $900 billion relief package into law, averting economic disaster.\n\"Without that, we would be in a double dip recession,\" said Zandi, the Moody's economist.\nSlammed by the pandemic, the US economy limped to the end of 2020 and started this year slowly. In December, employers cut jobs in for the first time since the spring. And the United States added just 49,000 jobs in January.\nJobless claims remain alarmingly high. Another 793,000 Americans filed for first time unemployment benefits last week alone. For context, that is above the worst levels of the Great Recession.\nVaccines to the rescue\nBut there are glimmers of hope on the pandemic. Although Covid deaths remain unthinkably high, hospitalizations and cases have retreated.\nCritically, the rollout of coronavirus vaccines is accelerating. Out of a total of 66 million vaccines distributed, about 70% have been administered, according to Morgan Stanley.\nAnd Dr. Anthony Fauci, the nation's top infectious disease expert,told NBC News Thursday that the United States may be able to vaccinate most Americans by the middle or end of summer.\nAll of this has allowed states including California, New York and New Jersey to relax health restrictions crushing restaurants and other small businesses.\nThat's not to say the pandemic is over. In fact,one risk is that new Covid-19 variants force US states and cities to once again tighten health restrictions.\nLow-wage workers are still hurting badly\nAgainst this backdrop, many economists are urging Washington to push ahead with plans for aggressive fiscal stimulus.\n\"Foot flat on the accelerator, please,\" Zandi, the Moody's economist said. \"Policymaking 101 says err on the side of doing too much, rather than too little.\"\nDoing too little risks worsening America's inequality problem. That's because this recession, more than prior ones, disproportionately hurt low-income workers in hard-hit sectors such as restaurants, childcare and hospitality.\nEmployment levels of low-wage workers (those making less than $27,000 per year) is still down more than 20%, according to the Opportunity Insights Economic tracker. By contrast, employment levels of those making more than $60,000 per year are above pre-crisis levels.\n\"Biden's team is unlikely to break out the champagne over reaching full employment if it isn't evident across income and racial groups,\" economists at Bank of America wrote in a report to clients.\nHowever, Danielle DiMartino Booth, a former Fed official who is now CEO of Quill Intelligence, worries the focus on providing income, instead of investing in infrastructure and reskilling workers, will make the country addicted to stimulus.\n\"The economy is going to turn into this dependent patient, always waiting for the next injection,\" Booth said.\n'Bring it on'\nSome economists, including former Treasury Secretary Larry Summers, have warned there is a risk that Washington overheats the economy by injecting too much support.\n\"You could have quite the inflation scare in the next few months that will test the bond market and the Fed,\" Booth said.\nAnd that in turn would spook the red-hot stock market.\nFed watchers are moving up their timelines for when the central bank will be able to end its emergency policies.\nCiting \"signs of a firmer inflation outlook,\" Goldman Sachs now expects the Fed to start \"tapering\" its asset purchases in early 2022 and to raise interest rates in the first half of 2024.\nZandi isn't losing sleep over inflation, mostly because the United States is far from full employment.\n\"It's a vastly overstated worry,\" he said. \"Bring it on. Our biggest problem for more than a decade has been low inflation. Higher inflation would be a high-class problem to have.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":361,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":314536981,"gmtCreate":1612361725943,"gmtModify":1703760838480,"author":{"id":"3563929170003666","authorId":"3563929170003666","name":"HongWang","avatar":"https://static.tigerbbs.com/98c4dd0e0d1f9e2e40e2885b36ade4a0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[开心] ","listText":"[开心] ","text":"[开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/314536981","repostId":"2108275621","repostType":4,"isVote":1,"tweetType":1,"viewCount":317,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":314594334,"gmtCreate":1612361294728,"gmtModify":1703760828492,"author":{"id":"3563929170003666","authorId":"3563929170003666","name":"HongWang","avatar":"https://static.tigerbbs.com/98c4dd0e0d1f9e2e40e2885b36ade4a0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[微笑] ","listText":"[微笑] ","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/314594334","repostId":"2108876804","repostType":4,"repost":{"id":"2108876804","pubTimestamp":1612348872,"share":"https://www.laohu8.com/m/news/2108876804?lang=&edition=full","pubTime":"2021-02-03 18:41","market":"sg","language":"en","title":"Neo Group to acquire 51% stake in snack maker","url":"https://stock-news.laohu8.com/highlight/detail?id=2108876804","media":"businesstimes","summary":"\n \n CATALIST-LISTED food caterer Neo Group is acquiring a 51 per cent stake in local snack manufacturer Royale International Food Industries (RIFI) for S$1.02 million in cash, it said in an exchange filing on Wednesday.\n \n","content":"<div>\n<p>CATALIST-LISTED food caterer Neo Group is acquiring a 51 per cent stake in local snack manufacturer Royale International Food Industries (RIFI) for S$1.02 million in cash, it said in an exchange ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/neo-group-to-acquire-51-stake-in-snack-maker\">Web Link</a>\n\n</div>\n","source":"bustime_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neo Group to acquire 51% stake in snack maker</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeo Group to acquire 51% stake in snack maker\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-03 18:41 GMT+8 <a href=https://www.businesstimes.com.sg/companies-markets/neo-group-to-acquire-51-stake-in-snack-maker><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CATALIST-LISTED food caterer Neo Group is acquiring a 51 per cent stake in local snack manufacturer Royale International Food Industries (RIFI) for S$1.02 million in cash, it said in an exchange ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/neo-group-to-acquire-51-stake-in-snack-maker\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.businesstimes.com.sg/companies-markets/neo-group-to-acquire-51-stake-in-snack-maker","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2108876804","content_text":"CATALIST-LISTED food caterer Neo Group is acquiring a 51 per cent stake in local snack manufacturer Royale International Food Industries (RIFI) for S$1.02 million in cash, it said in an exchange filing on Wednesday.\nThe proposed acquisition is being carried out via wholly-owned subsidiary Thong Siek Global, with the consideration financed by internal cash resources and/or bank borrowings.\nNeo Group's chairman and chief executive officer Neo Kah Kiat said the move is a \"strategic fit\" for its food-manufacturing business, and the diversification into snack food products will broaden the group's revenue stream, with the added benefit of expanding into new overseas markets.\nRIFI is principally engaged in the manufacture of snacks under its flagship brand, Crusty's, with a selection of ready-to-eat products such as potato chips, fish skin and soy-based snacks. Neo Group said these snacks are available locally in Singapore, and also exported and sold in overseas markets such as Australia, China, the US and Malaysia.\nMr Neo said: \"In line with our growth strategies, we intend to actively expand our product offerings to cater to different market segments, to meet changing consumer demand and capture growth opportunities in snacks and ready-to-eat products.\n\"This earnings-accretive acquisition will also allow us to create new income streams, drive our export sales to new and existing markets worldwide, tapping both parties' well-established network across over 30 countries globally.\"\nNeo Group said the proposed acquisition is not expected to have any material impact on the group's consolidated net tangible assets or earnings per share for its current financial year ending March 31.\nShares of Neo Group fell one per cent or 0.5 Singapore cent on Wednesday to close at 52.5 cents before the announcement.","news_type":1},"isVote":1,"tweetType":1,"viewCount":543,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
